- Home
- OSBC vs CVAC Comparison
OSBC vs CVAC Comparison
Compare OSBC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSBC | CVAC |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 952.7M | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OSBC | CVAC |
|---|---|---|
| Price | $19.78 | $4.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $21.63 | $6.83 |
| AVG Volume (30 Days) | 271.8K | ★ 1.7M |
| Earning Date | 01-21-2026 | 11-24-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | ★ 1.48 | 0.94 |
| Revenue | ★ $288,832,000.00 | $83,000,117.00 |
| Revenue This Year | $27.60 | N/A |
| Revenue Next Year | $12.41 | $23.71 |
| P/E Ratio | $13.47 | ★ $4.59 |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $14.14 | $2.48 |
| 52 Week High | $20.96 | $5.72 |
Technical Indicators
Market Signals| Indicator | OSBC | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 33.03 |
| Support Level | $19.71 | $4.00 |
| Resistance Level | $20.60 | $4.36 |
| Average True Range (ATR) | 0.40 | 0.16 |
| MACD | -0.13 | -0.05 |
| Stochastic Oscillator | 6.00 | 27.27 |
Price Performance
Historical ComparisonAbout OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The Company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.